| Autor: |
María Bermejo González, Rafael Campos Cuerva, Beatriz Fernández Muñoz, Cristina Rosell‐Valle, María Martín López, Blanca Arribas Arribas, Migue Ángel Montiel, Gloria Carmona Sánchez, Mónica Santos González |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
TransfusionREFERENCES. 62(9) |
| ISSN: |
1537-2995 |
| Popis: |
Human platelet lysate (HPL) has been proposed as a safe and efficient xeno-free alternative to fetal bovine serum (FBS) for large-scale culturing of cell-based medicinal products. However, the use of blood derivatives poses a potential risk of pathogen transmission. To mitigate this risk, different pathogen reduction treatment (PRT) practices can be applied on starting materials or on final products, but these methods might modify the final composition and the quality of the products.We evaluated the impact of applying a PRT based on riboflavin and ultraviolet irradiation on the raw materials used to manufacture an improved Good Manufacturing Practices (GMP)-grade HPL product in a public blood center. Growth promotion and the levels of growth factors and proteins were compared between an inactivated product (HPL4-i) and a non-inactivated product (HPL4). Stability studies were performed at 4°C, -20°C, and -80°C.The application of a PRT on the starting materials significantly altered the protein composition of HPL4-i as compared with HPL4. Despite this, the growth promoting rates were unaffected when compared with FBS used as a control. While all products were stable at -20°C and -80°C for 24 months, a significant decrease in the activity of HPL4-i was observed when stored at 4°C.Our results show that the application of a PRT based on riboflavin and ultraviolet light on starting materials used in the manufacture of HPL modifies the final composition of the product, yet its cell growth promoting activity is maintained at levels similar to those of non-inactivated products. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text